Abstract:Abstract Background: Tumor heterogeneity and changes in epidermal growth factor receptor (EGFR) expression status over time post challenges for the design of strategies for effective anti-EGFR monoclonal antibodies in the treatment of non-small-cell lung cancer (NSCLC). Therefore, there is an urgent need to develop techniques for real-time and comprehensive tumor EGFR profiling especially in lung cancer precision medicine trials. Radionuclide imaging of EGFR expression in tumors may screen patients for EGFR-targeting therapies and predict response or resistance to certain treatments. Methods: EGFR-specific Affibody molecule (Z EGFR:1907 ) was radiolabeled with 68 Ga. The radioligands were characterized in vitro and in mice bearing subcutaneous tumors with varying levels of EGFR expression: HCC827 (EGFR overexpression), H1975 (moderate-high), A549 (moderate), H358 (low), and H520 (negative). In vivo tumor targeting activity using PET imaging and biodistribution were conducted in tumor-bearing nude mice. Autoradiography, western blot, immunofluorescence, and immunohistochemistry were performed in human tumor samples. Statistical analyses were performed using GraphPad Prism 7.0. One-way or two-way analysis of variance (ANOVA) followed by the Bonferroni’s multiple comparisons test was used. Statistical significance was set at P < 0.05. Results: 68 Ga-NOTA-Z EGFR:1907 showed higher uptake in high EGFR-expressing cells (HCC827, H1975) when compared to cells with moderate to low EGFR (A549, H358) or without EGFR (H520). Radionuclide imaging showed probe accumulation was preferential in EGFR-expressing tumors, particularly in HCC827, H1975 xenografts. A549 and H358 xenografts were mildly and indistinctly visualized. EGFR-negative H520 xenografts were barely visible at any time-point. Biodistribution showed a significantly higher accumulation in HCC827 tumors when compared to H520 tumors (3.20 ± 0.10 %ID/g vs. 0.81 ± 0.08 %ID/g at 2h, P < 0.05). Specific binding to EGFR could be competitively blocked by excess un-radiolabeled affibody molecules in cell uptake, PET imaging and biodistribution assays. Autoradiography showed the regions with high radiotracer uptake partly overlapped with the area of positive EGFR immunofluorescence and immunohistochemistry. Finally, the overall accumulation of autoradiography was positively correlated with immunohistochemistry score. Conclusion: Affibody-based radiotracer 68 Ga-NOTA-Z EGFR:1907 is suitable for identification of EGFR expression, showing great potential for further applications and clinical translation.

Selective Uptake and Imaging of Aptamer- and Antibody-Conjugated Hollow Nanospheres Targeted to Epidermal Growth Factor Receptors Overexpressed in Head and Neck Cancer.

In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy.

Highly Selective Detection of Epidermal Growth Factor Receptor by Multifunctional Gold-Nanoparticle-based Resonance Rayleigh Scattering Method

Single Chain Epidermal Growth Factor Receptor Antibody Conjugated Nanoparticles for in Vivo Tumor Targeting and Imaging

Investigating the specific uptake of EGF-conjugated nanoparticles in lung cancer cells using fluorescence imaging

EGF-coated Gold Nanoparticles Provide an Efficient Nano-Scale Delivery System for the Molecular Radiotherapy of EGFR-positive Cancer

EGFR Antibody Conjugated Bimetallic Au@Ag Nanorods for Enhanced SERS-Based Tumor Boundary Identification, Targeted Photoacoustic Imaging and Photothermal Therapy

Accumulation of 111In-Labelled EGF-Au-PEG Nanoparticles in EGFR-Positive Tumours is Enhanced by Coadministration of Targeting Ligand.

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer

Thin Layer-Protected Gold Nanoparticles for Targeted Multimodal Imaging with Photoacoustic and CT

Resonance Rayleigh scattering detection of the epidermal growth factor receptor based on an aptamer-functionalized gold-nanoparticle probe

A Conjugated Aptamer and Oligonucleotides-Stabilized Gold Nanoclusters Nanoplatform for Targeted Fluorescent Imaging and Efficient Drug Delivery

Targeted imaging of EGFR overexpressed cancer cells by brightly fluorescent nanoparticles conjugated with cetuximab.

Surface Enhanced Raman Scattering Probes Based on Antibody Conjugated Au Nanostars for Distinguishing Lung Cancer Cells from Normal Cells

Characterization of 177Lu-Affibody-hsa Bioconjugate for Radionuclide Therapy of Egfr-Expressing Head and Neck Carcinomas

Dual targeting luminescent gold nanoclusters for tumor imaging and deep tissue therapy

Epidermal growth factor receptors siRNA-conjugated collagen modified gold nanoparticles for targeted imaging and therapy of lung cancer

Photo-controlled Aptamers Delivery by Dual Surface Gold-Magnetic Nanoparticles for Targeted Cancer Therapy.

A Gold Nanocage/Cluster Hybrid Structure for Whole-Body Multispectral Optoacoustic Tomography Imaging, EGFR Inhibitor Delivery, and Photothermal Therapy

Data from Targeted Photothermal Ablation of Murine Melanomas with Melanocyte-Stimulating Hormone Analog–Conjugated Hollow Gold Nanospheres

Affibody Molecule for Positron Emission Tomography Imaging of Human Epidermal Growth Factor Receptor: Validation in Mouse Models and Human Cancer Tissues